Phase 4 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults who have been diagnosed with B-cell lymphoma that has come back or has not responded to treatment, and who have already completed an initial course of treatment with a therapy called Relma-cel.
- People who have had at least one check-up to assess their disease after their first Relma-cel treatment, and whose doctor has decided a second round of treatment is appropriate.
- People for whom a sufficient dose of Relma-cel is available and confirmed before the second treatment (the recommended amount is 80–150 x 10⁶ CAR-T cells, with the exact dose decided by the treating doctor).
- People whose tumor cells have been confirmed to carry a marker called CD19, where it is safe and practical to check for this.
- People whose blood has been tested before the second treatment and shows no antibodies that would work against the Relma-cel therapy.
- People whose side effects from the preparatory chemotherapy (a regimen using two drugs called fludarabine and cyclophosphamide) have mostly cleared up — down to a mild level or back to their normal baseline — before the second treatment, with the exception of hair loss.
- People who either did not experience serious side effects during their first Relma-cel treatment, or whose side effects have fully resolved back to their baseline levels since that first treatment.
- People who have signed a form giving their informed consent to take part in the trial.
Who may not be able to join:
- People who have a known allergic reaction or sensitivity to any of the ingredients in Relma-cel, including substances used in its preparation such as dimethyl sulfoxide, a compound electrolyte solution, or human albumin.
- People who have an infection — such as a fungal, bacterial, viral, or other type of infection — that is not currently under control.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 021-64370045
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective Response Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.